Literature DB >> 19846533

A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Anthony C Wong1, Rohini G Sandesara, Nirupama Mulherkar, Sean P Whelan, Kartik Chandran.   

Abstract

Ebolavirus (EBOV) entry into cells requires proteolytic disassembly of the viral glycoprotein, GP. This proteolytic processing, unusually extensive for an enveloped virus entry protein, is mediated by cysteine cathepsins, a family of endosomal/lysosomal proteases. Previous work has shown that cleavage of GP by cathepsin B (CatB) is specifically required to generate a critical entry intermediate. The functions of this intermediate are not well understood. We used a forward genetic strategy to investigate this CatB-dependent step. Specifically, we generated a replication-competent recombinant vesicular stomatitis virus bearing EBOV GP as its sole entry glycoprotein and used it to select viral mutants resistant to a CatB inhibitor. We obtained mutations at six amino acid positions in GP that independently confer complete resistance. All of the mutations reside at or near the GP1-GP2 intersubunit interface in the membrane-proximal base of the prefusion GP trimer. This region forms a part of the "clamp" that holds the fusion subunit GP2 in its metastable prefusion conformation. Biochemical studies suggest that most of the mutations confer CatB independence not by altering specific cleavage sites in GP but rather by inducing conformational rearrangements in the prefusion GP trimer that dramatically enhance its susceptibility to proteolysis. The remaining mutants did not show the preceding behavior, indicating the existence of multiple mechanisms for acquiring CatB independence during entry. Altogether, our findings suggest that CatB cleavage is required to facilitate the triggering of viral membrane fusion by destabilizing the prefusion conformation of EBOV GP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19846533      PMCID: PMC2798398          DOI: 10.1128/JVI.01832-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

Authors:  Kathleen M Daddario-DiCaprio; Thomas W Geisbert; Joan B Geisbert; Ute Ströher; Lisa E Hensley; Allen Grolla; Elizabeth A Fritz; Friederike Feldmann; Heinz Feldmann; Steven M Jones
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates.

Authors:  Gabriele Neumann; Thomas W Geisbert; Hideki Ebihara; Joan B Geisbert; Kathleen M Daddario-DiCaprio; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Authors:  Graham Simmons; Dhaval N Gosalia; Andrew J Rennekamp; Jacqueline D Reeves; Scott L Diamond; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

4.  Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain.

Authors:  Osvaldo Martinez; Charalampos Valmas; Christopher F Basler
Journal:  Virology       Date:  2007-04-16       Impact factor: 3.616

5.  Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.

Authors:  Sean M Amberg; Robert C Netter; Graham Simmons; Paul Bates
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.

Authors:  Melinda A Brindley; Laura Hughes; Autumn Ruiz; Paul B McCray; Anthony Sanchez; David A Sanders; Wendy Maury
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

7.  Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.

Authors:  M Porotto; P Carta; Y Deng; G E Kellogg; M Whitt; M Lu; B A Mungall; A Moscona
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

8.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.

Authors:  Sagar U Kapadia; John K Rose; Elaine Lamirande; Leatrice Vogel; Kanta Subbarao; Anjeanette Roberts
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616

9.  SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.

Authors:  I-Chueh Huang; Berend Jan Bosch; Fang Li; Wenhui Li; Kyoung Hoa Lee; Sorina Ghiran; Natalya Vasilieva; Terence S Dermody; Stephen C Harrison; Philip R Dormitzer; Michael Farzan; Peter J M Rottier; Hyeryun Choe
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

10.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes.

Authors:  Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

View more
  95 in total

1.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

3.  Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Authors:  Anna Z Wec; Zachary A Bornholdt; Shihua He; Andrew S Herbert; Eileen Goodwin; Ariel S Wirchnianski; Bronwyn M Gunn; Zirui Zhang; Wenjun Zhu; Guodong Liu; Dafna M Abelson; Crystal L Moyer; Rohit K Jangra; Rebekah M James; Russell R Bakken; Natasha Bohorova; Ognian Bohorov; Do H Kim; Michael H Pauly; Jesus Velasco; Robert H Bortz; Kevin J Whaley; Tracey Goldstein; Simon J Anthony; Galit Alter; Laura M Walker; John M Dye; Larry Zeitlin; Xiangguo Qiu; Kartik Chandran
Journal:  Cell Host Microbe       Date:  2019-01-09       Impact factor: 21.023

4.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

5.  Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Authors:  Anna Z Wec; Andrew S Herbert; Charles D Murin; Elisabeth K Nyakatura; Dafna M Abelson; J Maximilian Fels; Shihua He; Rebekah M James; Marc-Antoine de La Vega; Wenjun Zhu; Russell R Bakken; Eileen Goodwin; Hannah L Turner; Rohit K Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R Lai; Laura M Walker; Andrew B Ward; John M Dye; Kartik Chandran; Zachary A Bornholdt
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

6.  Protocadherin-1 is essential for cell entry by New World hantaviruses.

Authors:  Rohit K Jangra; Andrew S Herbert; Rong Li; Lucas T Jae; Lara M Kleinfelter; Megan M Slough; Sarah L Barker; Pablo Guardado-Calvo; Gleyder Román-Sosa; M Eugenia Dieterle; Ana I Kuehne; Nicolás A Muena; Ariel S Wirchnianski; Elisabeth K Nyakatura; J Maximilian Fels; Melinda Ng; Eva Mittler; James Pan; Sushma Bharrhan; Anna Z Wec; Jonathan R Lai; Sachdev S Sidhu; Nicole D Tischler; Félix A Rey; Jason Moffat; Thijn R Brummelkamp; Zhongde Wang; John M Dye; Kartik Chandran
Journal:  Nature       Date:  2018-11-21       Impact factor: 49.962

Review 7.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

8.  Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.

Authors:  Lauren K Regula; Richard Harris; Fang Wang; Chelsea D Higgins; Jayne F Koellhoffer; Yue Zhao; Kartik Chandran; Jianmin Gao; Mark E Girvin; Jonathan R Lai
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

9.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

10.  Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Authors:  Erica Ollmann Saphire; Sharon L Schendel; Marnie L Fusco; Karthik Gangavarapu; Bronwyn M Gunn; Anna Z Wec; Peter J Halfmann; Jennifer M Brannan; Andrew S Herbert; Xiangguo Qiu; Kshitij Wagh; Shihua He; Elena E Giorgi; James Theiler; Kathleen B J Pommert; Tyler B Krause; Hannah L Turner; Charles D Murin; Jesper Pallesen; Edgar Davidson; Rafi Ahmed; M Javad Aman; Alexander Bukreyev; Dennis R Burton; James E Crowe; Carl W Davis; George Georgiou; Florian Krammer; Christos A Kyratsous; Jonathan R Lai; Cory Nykiforuk; Michael H Pauly; Pramila Rijal; Ayato Takada; Alain R Townsend; Viktor Volchkov; Laura M Walker; Cheng-I Wang; Larry Zeitlin; Benjamin J Doranz; Andrew B Ward; Bette Korber; Gary P Kobinger; Kristian G Andersen; Yoshihiro Kawaoka; Galit Alter; Kartik Chandran; John M Dye
Journal:  Cell       Date:  2018-08-09       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.